- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04767191
Malaria Therapeutic Efficacy Study (TES) Kenya (Kenya-TES)
Efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Siaya and Bungoma Counties, Kenya
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
WHO recommends that Therapeutic Efficacy Studies (TES) for 1st and 2nd line antimalarial medicines should be routinely carried out and data made available for decision-making due to the threat of emergence and spread of artemisinin resistance in malaria-endemic countries, especially in Africa. In its strategy to strengthen malaria surveillance, Kenya's Ministry of Health (MOH) National Malaria Program (NMP) planned to conduct TES every three years to ascertain continuing efficacy of the first and second-line treatments. The last TES for 1st line treatment of malaria in Kenya was done in Siaya county in 2016. In line with the WHO recommendation, Jhpiego Impact Malaria project in Kenya, with funding and technical oversight from Center for Disease Prevention and Control (CDC) will be supporting the Kenya MOH NMP to conduct a TES to assess the efficacy of the current first and second line treatment policy in Kenya. The study is being conducted by Kenya MOH NMP, with technical oversight and funding by CDC through the Jhpiego Impact Malaria project in Kenya.
Objective: To assess the efficacy of Artemether Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DHP) for the treatment of uncomplicated P. falciparum malaria infections.
Study Sites: One site will be selected in Siaya county and one site will be selected in Bungoma county (Kimilili Sub-County). Both sites will be Level-2 facilities (health centers) with high outpatient department attendance of patients with malaria. At each site, there will be two study arms: one arm for AL and one arm for DHP.
Study Period: March 2021 to September 2021
Study Design: This surveillance study is a two-arm prospective study Patient population: Febrile patients aged between 6 months and 59 months, with confirmed uncomplicated P. falciparum monoinfection.
Sample Size: At each site, at least 100 patients will be enrolled per drug (200 patients per site, 400 patients total).
Treatment(s) and follow-up: Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate AL efficacy, and over a 42-day follow-up period to evaluate DHP efficacy.
Primary endpoints: The proportion of patients with early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response as indicators of efficacy. Recrudescence will be distinguished from re-infection by polymerase chain reaction (PCR) analysis.
Secondary endpoints: The frequency and nature of adverse events.
Exploratory endpoints: to determine the polymorphism of molecular markers of drug resistance and evasion of diagnostic testing; to determine the blood concentration of AL
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Dickson Mwakangalu, MD
- Phone Number: +254722726184
- Email: Dickson.Mwakangalu@jhpiego.org
Study Locations
-
-
Bungoma County
-
Bungoma, Bungoma County, Kenya
- Makhonge Health Centre
-
-
Siaya County
-
Siaya, Siaya County, Kenya
- Kaluo Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age between 6 months to 59 months; mono-infection with P. falciparum confirmed by positive blood smear (i.e. no mixed infection);
- parasitaemia of 1,000 - 100,000/µl asexual forms;
- presence of axillary temperature ≥ 37.5 °C or history of fever during the past 24 h;
- ability to swallow oral medication;
- haemoglobin ≥5.0 g/dL at admission;
- informed consent from a parent or guardian;
- parent/guardian agrees to bring the patient for planned follow-up visits at day 7, 14, 21, and 28
Exclusion Criteria:
- general danger signs or signs of severe falciparum malaria according to the definitions of WHO;
- severe malnutrition according to WHO child growth standards (WHO, 2006), children with marasmus or oedematous malnutrition;
- mixed or mono-infection with another Plasmodium species detected by microscopy;
- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- regular medication, which may interfere with antimalarial pharmacokinetics;
- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- history of receiving any antimalarial treatment in the preceding 72 hours;. exposure to malaria vaccine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: artemether lumefantrine
The drug is approved and in use by the Kenya Ministry of Health as the 1st line treatment for malaria.
The study is to assess the continued efficacy of the drug.
|
The drugs are approved and in use by the Kenya Ministry of Health as the 1st and 2nd line treatment for malaria.
The study is to assess the continued efficacy of the two drugs in the treatment of uncomplicated malaria.
|
Active Comparator: dihydroartemisinin piperaquine
The drug is approved and in use by the Kenya Ministry of Health as the 2nd line treatment for malaria.
The study is to assess the continued efficacy of the drug.
|
Antimalarial Combinations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients (in the Artemether Lumefantrine arm) with clinical and parasitological cure (i.e. free of malaria symptoms and parasites) assessed clinically and via microscopy and rapid diagnostic test.
Time Frame: By day 28 post-treatment
|
By day 28 post-treatment
|
Number of patients (in the Dihydroartemisinin-Piperaquine arm) with clinical and parasitological cure (i.e. free of malaria symptoms and parasites) assessed clinically and via microscopy and rapid diagnostic test.
Time Frame: By day 42 post-treatment
|
By day 42 post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients (in the Artemether Lumefantrine arm arm) with treatment-related adverse events
Time Frame: by day 28 post-treatment
|
by day 28 post-treatment
|
Number of patients (in the Dihydroartemisinin-Piperaquine arm) with treatment-related adverse events
Time Frame: by day 42 post-treatment
|
by day 42 post-treatment
|
Number of patients (in the Artemether Lumefantrine arm) with molecular markers of drug resistance assessed via phenotype test
Time Frame: by day 28 post-treatment
|
by day 28 post-treatment
|
Number of patients (in the Dihydroartemisinin-Piperaquine arm) with molecular markers of drug resistance assessed via phenotype test
Time Frame: by day 42 post-treatment
|
by day 42 post-treatment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00012257
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Malaria
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia
-
U.S. Army Office of the Surgeon GeneralU.S. Army Medical Research and Development Command; Military Infectious Diseases...CompletedFalciparum Malaria | Uncomplicated MalariaKenya, Thailand
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Johns Hopkins Bloomberg School of Public HealthTropical Diseases Research CentreActive, not recruitingUncomplicated Falciparum MalariaZambia
-
University of OxfordMahidol University; Medicines for Malaria VentureWithdrawnUncomplicated Falciparum MalariaCambodia
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompleted
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
Clinical Trials on artemether lumefantrine
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of Cape TownLondon School of Hygiene and Tropical MedicineCompletedHIV | MalariaSouth Africa
-
University of OxfordUniversity of KinshasaCompleted
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Completed
-
Novartis PharmaceuticalsMedicines for Malaria VentureCompletedAcute Uncomplicated Falciparum MalariaBurkina Faso, Benin, Congo, Nigeria, Togo
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRecruitingHealthy | Pharmacokinetic | Drug CombinationThailand
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health Sciences and other collaboratorsRecruitingMalaria,FalciparumUganda
-
Novartis PharmaceuticalsCenters for Disease Control and PreventionCompletedMalariaUnited States
-
NovartisCompletedMalaria | FalciparumBenin, Kenya, Mali, Mozambique, Tanzania
-
Centers for Disease Control and PreventionIfakara Health Research and Development CentreCompleted